Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Prodrugs01:30

Prodrugs

3.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
3.8K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.1K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials.

Cancer chemotherapy and pharmacology·2026
Same author

Systematic identification of genomic nonresponse biomarkers to cancer therapies.

ESMO real world data and digital oncology·2026
Same author

Real-world effectiveness of molecular-matched therapies in salivary gland cancer.

ESMO open·2026
Same author

Prospective evaluation of genomics-guided off-label treatment.

Nature·2026
Same author

Artificial intelligence for clinical trial design, conduct, and analysis: a narrative review.

ESMO real world data and digital oncology·2026
Same author

Clinical text mining of the performance status and progression-free survival to facilitate data collection in cancer research: an exploratory study.

ESMO real world data and digital oncology·2026

相关实验视频

Updated: Jan 6, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物重新发现协议有助于扩大已有的抗癌药物的使用

D L van der Velden1,2, L R Hoes1,2,3, H van der Wijngaart2,3,4

  • 1Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Nature
|October 2, 2019
PubMed
概括
此摘要是机器生成的。

在使用非标签药物治疗的34%罕见癌症变异患者中,药物重新发现协议发现了临床益处. 这项精确瘤试验加速了新的癌症治疗见解, 并分享了未来治疗决策的知识.

更多相关视频

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

相关实验视频

Last Updated: Jan 6, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

科学领域:

  • 癌症学
  • 遗传学
  • 药理学

背景情况:

  • 大规模的瘤基因分析可以识别可操作的分子变异.
  • 没有系统地收集非标签药物使用的成功/失败情况.
  • 在精密瘤学中需要系统地收集数据.

研究的目的:

  • 启动药物重新发现方案, 一个适应精确瘤学试验.
  • 在特定患者群体中确定非标签抗癌药物使用的活性信号.
  • 在罕见的癌症小组中促进经批准的药物的标签之外的定义使用.

主要方法:

  • 适应性,精确瘤学试验设计.
  • 已耗尽/拒绝标准疗法和可行的变种的患者的招募.
  • 使用未经批准的标签进行向治疗或免疫治疗.

主要成果:

  • 在215名接受治疗的患者中,整体临床益处率为34% (136名向治疗,79名免疫治疗).
  • 临床益处的中位持续时间为9个月.
  • 鉴定了一组成功的微卫星不稳定瘤治疗nivolumab (63%的益处率).

结论:

  • 药物重新发现协议在罕见的癌症小组中促进非标签药物使用.
  • 识别活动的早期信号,加速新见解的临床转化.
  • 为未来的决策创建一个公共知识库.